About this trial
This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.
Primary Objective:
To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.
Feasibility will be assessed by:
* Participation Rate: Number of eligible survivors approached who enroll. * Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.
Participant is between the ages of >10 and <25 years old the time of enrollment.
Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.
Participant has been medically cleared to participate in physical activity.
Disqualifiers
Participant has evidence of relapsed disease.
Participant has a diagnosis of acute heart failure.
Participant reports currently participating in HIIT training or >420 minutes per week of moderate to vigorous physical activity.
Female participant who is currently pregnant.
Trial design
Single group
Treatments tested in this trial
High Intensity Interval Training (HIIT)
BehavioralParticipants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.
Treatment groups
Trial outcomes
Primary outcomes
Participation rate (percent of eligible participants approached who enroll)
Descriptive statistics will be reported
Completion rate (percentage of scheduled HIIT sessions attended and percentage of post-intervention testing sessions completed)
Descriptive statistics will be reported
Other outcomes
Cardiorespiratory fitness (VO2peak, ml/kg/min)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Ewing battery score of autonomic function (0 to 5 points)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Body mass index (weight and height will be combined to report body mass index in kg/m2)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Percent body fat (%)
Descriptive statistics of the change between baseline and 12 weeks will be reported
Sponsors and contacts
Click on the lead sponsor to view all of their trials.